关键信息
-
基因名
b4GALNT2
- 应用
-
别名
b4GALNT2；GALGT2；Beta-1.4 N-acetylgalactosaminyltransferase 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NHY0
-
表达区间
1-566aa
-
氨基酸序列
MGSAGFSVGKFHVEVASRGRECVSGTPECGNRLGSAGFGALCLELRGADPAWGPFAAHGRSRRQGSRFLWLLKILVIILVLGIVGFMFGSMFLQAVFSSPKPELPSPAPGVQKLKLLPEERLRNLFSYDGIWLFPKNQCKCEANKEQGGYNFQDAYGQSDLPAVKARRQAEFEHFQRREGLPRPLPLLVQPNLPFGYPVHGVEVMPLHTVPIPGLQFEGPDAPVYEVTLTASLGTLNTLADVPDSVVQGRGQKQLIISTSDRKLLKFILQHVTYTSTGYQHQKVDIVSLESRSSVAKFPVTIRHPVIPKLYDPGPERKLRNLVTIATKTFLRPHKLMIMLRSIREYYPDLTVIVADDSQKPLEIKDNHVEYYTMPFGKGWFAGRNLAISQVTTKYVLWVDDDFLFNEETKIEVLVDVLEKTELDVVGGSVLGNVFQFKLLLEQSENGACLHKRMGFFQPLDGFPSCVVTSGVVNFFLAHTERLQRVGFDPRLQRVAHSEFFIDGLGTLLVGSCPEVIIGHQSRSPVVDSELAALEKTYNTYRSNTLTRVQFKLALHYFKNHLQCAA
-
分子量
63.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
B4GALNT2, or Beta-1,4-N-acetylgalactosaminyltransferase 2, is an enzyme that plays a crucial role in the biosynthesis of glycoproteins and glycolipids. It is involved in the addition of N-acetylgalactosamine (GalNAc) to various sugar chains, particularly in the formation of glycosphingolipids, which are essential for cellular differentiation, growth, and signaling. Abnormalities in the function or expression of B4GALNT2 have been linked to several pathological conditions, including certain neurological disorders and cancers, indicating its potential as a biomarker or therapeutic target. Given the importance of glycosylation in diverse biological processes, research on recombinant B4GALNT2 proteins aims to elucidate their functional mechanisms, improve understanding of glycan structures, and develop novel strategies for disease intervention. Advances in recombinant protein technology have enabled the production of bioactive forms of B4GALNT2, facilitating the study of its enzymatic properties and interactions within the cellular milieu. This research is pivotal for exploring new avenues in glycoengineering, therapeutic glycoprotein design, and the understanding of glycan-mediated cellular interactions, ultimately contributing to innovative approaches in biomedicine and glycobiology.
